NEWS AND EVENTS
NEWS AND EVENTS
Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech
Palma, Spain and San Diego, USA, 23 September 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. In […]
Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise
– Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis – Round led by Spanish investor Caixa Capital Risc – Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to international consortium of existing shareholders Palma, Spain and San […]
Data from SNF472 Phase 1b Clinical Trial published in British Journal of Clinical Pharmacology
Data show SNF472 inhibits induction of HAP crystallization Results provide support for further development of SNF472 as a novel treatment for CUA Palma, Spain and San Diego, USA, 4 March, 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on the treatment of conditions related to progressive vascular calcification, today announces the publication in the […]
Sanifit highlights publication of “50 Key Questions on Calciphylaxis”
Palma, Spain and San Diego, USA, 21 November, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, is pleased to note the publication of ’50 Key Questions on Calciphylaxis in Chronic Kidney Disease’ by Dr José Vicente Torregrosa and Dr David Cucchiari, the printing of which was sponsored by Sanifit. […]
Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology
Palma, Spain and San Diego, USA, 23 October, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical […]
Latest News
UPCOMING EVENTS
11th-14th January – JPMorgan, San Francisco, USA
4th – 6th April – BIO Europe Spring, Stockholm, Sweden
27th April – 1st May – NKF Clinical Meeting, Boston, USA
21st – 24th May – ERA – EDTA, VIenna, Austria
6th – 9th June – BIO, San Francisco, USA
7th – 9th November – BIO Europe, Cologne, Germany
15th – 20th November – ASN Kidney Week, Chicago, USA